Views & Analysis True pharma-patient co-creation A recent MS patient group forum hosted by Merck KGaA demonstrates the power of true co-creation with patients.
Views & Analysis Getting MS diagnosis right MS advocate Trishna Bharadia explains how diagnosis needs to change and why pharma shouldn’t be using the word ‘patient’.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.